NCT06791161View on ClinicalTrials.gov

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Enrolling by invitationOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

January 19, 2025

Primary Completion Date

January 18, 2030

Study Completion Date

January 18, 2035

Conditions

Breast

Interventions

DRUG

Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor

BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER